Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926575 · ClinicalTrials.gov registry record · Phase 3
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
A Phase 3 study, sponsored by Soligenix.
- Terminated
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT00926575 is a Phase 3 study that was terminated before completion, run by Soligenix. The registered enrollment target is 140 participants.
The verdict
NCT00926575, a Phase 3 study, was terminated before completion, sponsored by Soligenix.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
Interventions
- DRUG Placebo
- DRUG oral beclomethasone 17,21-dipropionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00926575
The ClinicalTrials.gov registry entry for NCT00926575 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soligenix, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00926575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00926575 about?
NCT00926575 is a clinical study titled "Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)". Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
What is the current status of trial NCT00926575?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2009-10. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00926575?
The interventions under investigation include: Placebo (DRUG), oral beclomethasone 17,21-dipropionate (DRUG).
Who is sponsoring clinical trial NCT00926575?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.